ResMed Inc. 10-Q Summary: Period Ended December 31, 1997
Business Context and Reporting Period
This is an unaudited quarterly report (Form 10-Q) for ResMed Inc., a Delaware corporation holding ResMed Holdings Ltd., an Australian entity. The company designs, manufactures, and markets devices for sleep-disordered breathing, primarily obstructive sleep apnea. Principal manufacturing is located in Australia, with major distribution in the U.S., U.K., and Europe. The reporting period covers the three and six months ended December 31, 1997.
Key Financial Metrics
| Metric | 3 Months Ended Dec 31, 1997 | 6 Months Ended Dec 31, 1997 |
|---|---|---|
| Net Revenue | $16.1 million | $30.1 million |
| Gross Profit | $11.0 million | $19.5 million |
| Gross Margin | 68% | 65% |
| Operating Income | $4.7 million | $7.3 million |
| Net Income | $2.3 million | $4.4 million |
| Diluted EPS | $0.31 | $0.60 |
| Cash from Operations (6mo) | $1.3 million | |
| Cash & Equivalents (Dec 31, 1997) | $7.6 million | |
| Working Capital (Dec 31, 1997) | $29.3 million | |
| Total Debt | $358,000 (Current portion only) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 39% ($4.6 million) for the quarter and 33% ($7.4 million) for the six months compared to the prior year periods. Growth was driven by increased unit sales of flow generators and accessories, particularly in North America.
- Margin Expansion: Gross profit margins improved significantly, rising from 59% to 68% for the quarter and 58% to 65% for the six months. This was attributed to a shift to higher-margin products and a significant devaluation of the Australian Dollar (AUD), which reduces manufacturing costs in USD terms.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 22% for the quarter due to increased personnel (from 91 to 124). Research and development (R&D) expenses increased 38% for the quarter due to new product development and consultant usage.
- Foreign Exchange Impact: "Other income (expense), net" swung from a profit of $627,000 in the prior year quarter to a loss of $1.2 million. This was primarily due to $1.6 million in net foreign exchange losses on currency option contracts hedging the AUD.
- Capital Expenditures: Capital spending surged to $6.0 million for the six months (vs. $1.4 million prior year), largely for the construction of a new manufacturing facility in Sydney and purchase of equipment.
Outlook, Risks, and Contingencies
- Legal Proceedings: The company is engaged in significant patent litigation with Respironics in the U.S. regarding four patents. A partial summary judgment was granted to Respironics on one patent, which ResMed intends to appeal. Additionally, Respironics has filed a claim in Australia alleging unfair trade practices seeking approximately $730,000 in damages. Management expects to incur ongoing legal costs.
- Currency Risk: The company has substantial exposure to the Australian Dollar regarding manufacturing and R&D. While hedging strategies are in place, fluctuations in exchange rates continue to impact consolidated results, as evidenced by the recent foreign exchange losses.
- Liquidity: Working capital declined from $34.4 million to $29.3 million, primarily due to the purchase of a 173,000 sq. ft. site in Sydney. Cash and marketable securities totaled approximately $20.6 million as of December 31, 1997.
- Management Commentary: Management attributes strong performance to unit volume growth and favorable currency movements. They note that the Asian economic crisis is not anticipated to significantly impact the company, as only 2% of revenue is generated in Southeast Asia.
Investor Verification Checklist
- Patent Litigation Status: Verify the current status of the appeal regarding the partial summary judgment granted to Respironics and the potential financial impact of the Australian unfair trade practices claim.
- Foreign Exchange Hedging: Review the effectiveness of the company's hedging strategy given the recent $1.6 million loss on currency options and the volatility of the Australian Dollar.
- Capital Project Progress: Confirm the timeline and budget adherence for the new Sydney manufacturing facility, which drove a significant increase in capital expenditures.
- Revenue Concentration: Assess the sustainability of the 39% revenue growth, specifically the reliance on North American sales which saw a jump from $4.9 million to $8.3 million in the quarter.
- Inventory Levels: Monitor inventory levels, which increased from $5.8 million to $7.6 million, to ensure they align with sales growth and do not indicate obsolescence risks.